Skip to main content
Top
Published in: Annals of Hematology 8/2022

23-05-2022 | Systemic Lupus Erythematosus | Original Article

Prevalence and characteristics of inflammatory rheumatic diseases in patients with thalassemia

Authors: Pokpong Piriyakhuntorn, Adisak Tantiworawit, Nuntana Kasitanon, Worawit Louthrenoo

Published in: Annals of Hematology | Issue 8/2022

Login to get access

Abstract

Reports of inflammatory rheumatic diseases (IRD) in thalassemia are limited. This study aimed to determine the prevalence and clinical characteristics of IRD in patients with thalassemia disease. Consecutive adult patients with thalassemia disease, confirmed by hemoglobin typing, attending the Hematology Clinic between June 2019 and May 2021 were invited to join this study. All of them had their history taken and a physical examination for IRD. Those with IRD had their medical records reviewed. Sixty-three patients (transfusion-dependent in 50) were included in this study. There was α-, β-, and co-inheritance of α- and β-thalassemia in 22.22%, 73.02%, and 4.76% of the patients, respectively, with β-thalassemia/Hb E disease in 53.97%. Twenty-three patients had IRD (rheumatoid arthritis in 9, gout in 6, systemic lupus erythematosus in 3, spondyloarthropathy in 2, and one patient each with dermatomyositis, overlap syndrome, and unclassified polyarthralgia). Clinical manifestations and laboratory findings were similar to IRD patients in general. In 40 patients without IRD, direct and indirect Coombs tests and antinuclear antibody (ANA) were positive in 51.72%, 27.59%, and 10.26%, respectively. When comparing among these 40 patients, between those with non-transfusion-dependent thalassemia (n = 10) and those with transfusion-dependent thalassemia (n = 30), the latter had non-significantly more positive direct Coombs (60.87% vs. 16.67%), indirect Coombs (30.43% vs. 16.67%), and ANA tests (13.33% vs. 0%). The prevalence of IRD in patients with thalassemia disease was rather high. Positive direct Coombs test and ANA were common in transfusion-dependent patients.
Literature
9.
18.
25.
go back to reference Keenan RT, Nowatzky J, Pillinger MH (2013) Eitology and pathogenesis of hyperuricemia and gout. In: Firestein GS, Budd R, C., Gabriel S, E., McInnes IB, O’Dell JR, eds. Kelley’s textbook of rheumatology. Philadelphia: Elavier Saunders 1533:53 Keenan RT, Nowatzky J, Pillinger MH (2013) Eitology and pathogenesis of hyperuricemia and gout. In: Firestein GS, Budd R, C., Gabriel S, E., McInnes IB, O’Dell JR, eds. Kelley’s textbook of rheumatology. Philadelphia: Elavier Saunders 1533:53
28.
go back to reference Paik CH, Alavi I, Dunea G, Weiner L (1970) Thalassemia and gouty arthritis. JAMA 213(2):296–297CrossRef Paik CH, Alavi I, Dunea G, Weiner L (1970) Thalassemia and gouty arthritis. JAMA 213(2):296–297CrossRef
32.
go back to reference Voulgari PV, Karali A, Alymara V, Chaidos A, Bourantas KL, Drosos AA (2005) Systemic lupus erythematosus in a patient with beta-thalassemia major. Clin Exp Rheumatol 23(2):278PubMed Voulgari PV, Karali A, Alymara V, Chaidos A, Bourantas KL, Drosos AA (2005) Systemic lupus erythematosus in a patient with beta-thalassemia major. Clin Exp Rheumatol 23(2):278PubMed
34.
go back to reference Castellino G, Govoni M, Trotta F (2004) Beta-thalassaemic trait and systemic lupus erythematosus. Clin Exp Rheumatol 22(3):382–383PubMed Castellino G, Govoni M, Trotta F (2004) Beta-thalassaemic trait and systemic lupus erythematosus. Clin Exp Rheumatol 22(3):382–383PubMed
40.
go back to reference Arinsburg SA, Skerrett DL, Kleinert D, Giardina PJ, Cushing MM (2010) The significance of a positive DAT in thalassemia patients. Immunohematology 26(3):87–91CrossRef Arinsburg SA, Skerrett DL, Kleinert D, Giardina PJ, Cushing MM (2010) The significance of a positive DAT in thalassemia patients. Immunohematology 26(3):87–91CrossRef
41.
go back to reference Agarwal MB, Viswanathan C, Gupte SS, Desai NG, Vasandani D, Bhave AA (1992) Anti-nuclear antibody positivity in multi-transfused thalassemia major. Indian Pediatr 29(5):607–610PubMed Agarwal MB, Viswanathan C, Gupte SS, Desai NG, Vasandani D, Bhave AA (1992) Anti-nuclear antibody positivity in multi-transfused thalassemia major. Indian Pediatr 29(5):607–610PubMed
42.
go back to reference Winichakoon P, Tantiworawit A, Rattanathammethee T, Hantrakool S, Chai-Adisaksopha C, Rattarittamrong E et al (2015) Prevalence and risk factors for complications in patients with nontransfusion dependent alpha- and beta-thalassemia. Anemia 2015(793025. https://doi.org/10.1155/2015/793025 Winichakoon P, Tantiworawit A, Rattanathammethee T, Hantrakool S, Chai-Adisaksopha C, Rattarittamrong E et al (2015) Prevalence and risk factors for complications in patients with nontransfusion dependent alpha- and beta-thalassemia. Anemia 2015(793025. https://​doi.​org/​10.​1155/​2015/​793025
Metadata
Title
Prevalence and characteristics of inflammatory rheumatic diseases in patients with thalassemia
Authors
Pokpong Piriyakhuntorn
Adisak Tantiworawit
Nuntana Kasitanon
Worawit Louthrenoo
Publication date
23-05-2022
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 8/2022
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-022-04870-3

Other articles of this Issue 8/2022

Annals of Hematology 8/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.